305 related articles for article (PubMed ID: 21722671)
1. The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that provide potent protection from influenza A virus.
Suda T; Kawano M; Nogi Y; Ohno N; Akatsuka T; Matsui M
Antiviral Res; 2011 Sep; 91(3):252-8. PubMed ID: 21722671
[TBL] [Abstract][Full Text] [Related]
2. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
3. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza.
Deliyannis G; Kedzierska K; Lau YF; Zeng W; Turner SJ; Jackson DC; Brown LE
Eur J Immunol; 2006 Mar; 36(3):770-8. PubMed ID: 16435281
[TBL] [Abstract][Full Text] [Related]
4. Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts.
Malowany JI; McCormick S; Santosuosso M; Zhang X; Aoki N; Ngai P; Wang J; Leitch J; Bramson J; Wan Y; Xing Z
Mol Ther; 2006 Apr; 13(4):766-75. PubMed ID: 16343993
[TBL] [Abstract][Full Text] [Related]
5. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.
Tompkins SM; Zhao ZS; Lo CY; Misplon JA; Liu T; Ye Z; Hogan RJ; Wu Z; Benton KA; Tumpey TM; Epstein SL
Emerg Infect Dis; 2007 Mar; 13(3):426-35. PubMed ID: 17552096
[TBL] [Abstract][Full Text] [Related]
6. Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination.
Holst PJ; Ørskov C; Thomsen AR; Christensen JP
J Immunol; 2010 Apr; 184(8):4431-9. PubMed ID: 20212099
[TBL] [Abstract][Full Text] [Related]
7. Efficient vagina-to-lower respiratory tract immune trafficking in a murine model of influenza A virus infection.
Garulli B; Meola M; Stillitano MG; Kawaoka Y; Castrucci MR
Virology; 2007 May; 361(2):274-82. PubMed ID: 17222437
[TBL] [Abstract][Full Text] [Related]
8. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
9. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.
Bessa J; Schmitz N; Hinton HJ; Schwarz K; Jegerlehner A; Bachmann MF
Eur J Immunol; 2008 Jan; 38(1):114-26. PubMed ID: 18081037
[TBL] [Abstract][Full Text] [Related]
10. Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial.
Cerwenka A; Morgan TM; Dutton RW
J Immunol; 1999 Nov; 163(10):5535-43. PubMed ID: 10553081
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigen-specific CD8 T cells and enhances the duration of protection against influenza-induced respiratory disease.
Moraes TJ; Lin GH; Wen T; Watts TH
Vaccine; 2011 Aug; 29(37):6301-12. PubMed ID: 21704101
[TBL] [Abstract][Full Text] [Related]
12. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
[TBL] [Abstract][Full Text] [Related]
13. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).
Sipo I; Knauf M; Fechner H; Poller W; Planz O; Kurth R; Norley S
Vaccine; 2011 Feb; 29(8):1690-9. PubMed ID: 21195079
[TBL] [Abstract][Full Text] [Related]
14. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein.
Tamura S; Miyata K; Matsuo K; Asanuma H; Takahashi H; Nakajima K; Suzuki Y; Aizawa C; Kurata T
J Immunol; 1996 May; 156(10):3892-900. PubMed ID: 8621928
[TBL] [Abstract][Full Text] [Related]
15. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Fang F; Zheng M; Chen Z
Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
[TBL] [Abstract][Full Text] [Related]
16. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
[TBL] [Abstract][Full Text] [Related]
17. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.
Liew FY; Russell SM; Appleyard G; Brand CM; Beale J
Eur J Immunol; 1984 Apr; 14(4):350-6. PubMed ID: 6609824
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen.
Santosuosso M; Zhang X; McCormick S; Wang J; Hitt M; Xing Z
J Immunol; 2005 Jun; 174(12):7986-94. PubMed ID: 15944305
[TBL] [Abstract][Full Text] [Related]
19. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
[TBL] [Abstract][Full Text] [Related]
20. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
